NDA 206911 · Sun Pharm
Bromsite
Bromfenac Sodium · Ophthalmic
Last checked: Nov 20, 2026Latest source record: Mar 9, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Apr 8, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
64
15 Phase 3, 1 recruiting
FAERS reports
1,020
301 serious, 10 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 8, 2026.
BromSite (bromfenac ophthalmic solution) 0.075% is indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery. BromSite is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery. (1)
Mechanism: Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- BROMSITE · BROMFENAC SODIUM EQ 0.075% ACID · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Bromfenac" as an intervention, any sponsor and status, largest first.
- PRevention of Macular EDema After Cataract SurgeryPivotal-lookingCompleted
Maastricht University Medical CenterAcademic, hospital or other
NCT01774474 · 1,127 participants · Start Jul 10, 2013 · Primary completion Nov 4, 2016
Drug: Bromfenac; Dexamethasone and 2 more · For: Cystoid Macular Edema; Cataract; Diabetes Mellitus
Sites: Vienna, Austria; Edegem, Belgium; Frankfurt am Main, Germany · 16 sites in all
- A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye DiseasePivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01212471 · 840 participants · Start Sep 2010 · Primary completion Aug 2011
Drug: Bromfenac Ophthalmic Solution A; Bromfenac Ophthalmic Solution B and 1 more · For: Dry Eye Syndrome
Sites: Irvine, California
- Effectiveness of Periocular Drug Injection in CATaract SurgeryPivotal-lookingTerminated
Luigi RondasAcademic, hospital or other
NCT05158699 · 628 participants · Start Oct 13, 2021 · Primary completion Aug 13, 2024
Drug: Bromfenac; Dexamethasone and 2 more · For: Macular Edema; Cystoid Macular Edema; Retinal Disease and 3 more
Sites: Vienna, Austria; Frankfurt am Main, Germany; Breda, Netherlands · 10 sites in all
- Efficacy and Safety of Bromfenac Ophthalmic SolutionPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00585975 · 568 participants · Start Oct 2007 · Primary completion Jul 2008
Drug: bromfenac ophthalmic solution · For: Cataract Surgery
Sites: Irvine, California
- Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract SurgeryPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00198445 · 527 participants · Start May 2003 · Primary completion Jan 2004
Drug: Bromfenac; Placebo · For: Postoperative Complications; Cataract
Sites: Birmingham, Alabama; Little Rock, Arkansas; Irvine, California · 39 sites in all
- Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract SurgeryPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00333918 · 522 participants · Start Jun 2006 · Primary completion Mar 2007
Drug: bromfenac ophthalmic solution; placebo comparator · For: Pain; Inflammation
Sites: Irvine, California
- Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract SurgeryPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01367249 · 440 participants · Start May 2011 · Primary completion Jul 2011
Drug: Bromfenac Ophthalmic Solution; Placebo · For: Pain; Inflammation; Cataract
Sites: Irvine, California
- Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract SurgeryPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00853970 · 299 participants · Start Feb 2009 · Primary completion Sep 2009
Drug: Bromfenac Ophthalmic Solution; Placebo Comparator · For: Pain; Inflammation
Sites: Irvine, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- treatment failure146
- product packaging quantity issue76
- off label use75
- product dose omission issue69
- drug ineffective64
- eye pain63
- eye irritation58
- product storage error39
- product use issue36
- visual impairment29
- ocular hyperaemia28
- product quality issue28
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 17 |
| 2013 | 7 |
| 2014 | 8 |
| 2015 | 17 |
| 2016 | 11 |
| 2017 | 88 |
| 2018 | 105 |
| 2019 | 78 |
| 2020 | 261 |
| 2021 | 73 |
| 2022 | 57 |
| 2023 | 75 |
| 2024 | 83 |
| 2025 | 63 |
| 2026 | 69 |
Recalls
1 FDA enforcement reports for this application.
Jan 24, 2019 · Class II · Terminated
Bromfenac Ophthalmic Solution, 0.075% (Sterile 5 mL) may have a lack of sterility assurance.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Bromsite (Bromfenac Sodium)
2024 spending
$1.4M
Beneficiaries
2,644
5,089 claims
Per beneficiary
$527
$51.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $9,978,649 |
| 2021 | $9,705,014 |
| 2022 | $6,630,113 |
| 2023 | $3,733,045 |
| 2024 | $1,393,888 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical bromfenac reduces multiple inflammatory cytokines in the aqueous humour of pseudophakic patients.
Matsumura T, Iwasaki K, Arimura S, et al. · Sci Rep 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema.
Gabr AF, Kamel MF, Elbarawy AA · Int Ophthalmol 2023 · Randomized Controlled Trial
- Topical non-steroidal anti-inflammatory agents for diabetic cystoid macular oedema.
Sahoo S, Barua A, Myint KT, et al. · Cochrane Database Syst Rev 2015 · Research Support, Non-U.S. Gov't, Systematic Review
- Topical bromfenac in VEGF-driven maculopathies: topical review and meta-analysis.
Kulikov AN, Vasiliev AS, Kalinicheva YA, et al. · BMC Ophthalmol 2024 · Meta-Analysis, Review
- COMPARISON OF THE EFFECTS OF EIGHT DIFFERENT TOPICAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS ON REDUCING INTRAVITREAL INJECTION-INDUCED PAIN.
SakallioĞlu AK, Kaya S, Garp R, et al. · Retina 2024 · Randomized Controlled Trial, Comparative Study
- Topical NSAIDs effect on corneal sensitivity.
Singer DD, Kennedy J, Wittpenn JR · Cornea 2015 · Randomized Controlled Trial
Sponsor: Sun Pharm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.